Health Care & Life Sciences » Biotechnology | Anterogen Co. Ltd.

Anterogen Co. Ltd. | Cash Flow

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
Net Income before Extraordinaries
1,810
1,416
58
372
739
Depreciation, Depletion & Amortization
254
264
292
311
391
Other Funds
-
-
154
219
212
Funds from Operations
995
650
550
1,322
1,342
Changes in Working Capital
483
361
295
1,453
671
Net Operating Cash Flow
1,478
1,010
844
131
671
Capital Expenditures
601
762
659
6,059
1,851
Sale of Fixed Assets & Businesses
21
4
18
40
48
Purchase/Sale of Investments
7,311
1,971
602
8,935
13,856
Net Investing Cash Flow
7,491
1,590
1,308
14,954
15,659
Issuance/Reduction of Debt, Net
-
-
-
-
10,000
Net Financing Cash Flow
7,534
-
3,604
16,942
20,210
Net Change in Cash
1,437
579
3,129
1,898
5,167
Free Cash Flow
1,740
1,166
566
5,156
34
Other Sources
400
380
895
-
1
Change in Capital Stock
7,534
-
3,450
16,723
9,998
Exchange Rate Effect
2
-
12
41
55
Other Uses
-
3
960
-
-

About Anterogen Co.

View Profile
Address
Unit 405, Namsung Plaza
Seoul SL 08589
Korea, Republic Of
Employees -
Website http://www.anterogen.com
Updated 09/14/2018
Anterogen Co., Ltd. develops stem cell therapy treatments. Its products include Cupistem and Remodullin injection, Queencell and stem cell conditioned media. In addition, It also offers stem cell banking and analysis services.